NCT Number: NCT04421222
Phase: Phase 1
Trial Summary: This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will recei – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ESSA Pharmaceuticals
Acronym: EPI-7386
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives